Healthtech Startup CURAPOD Raises Rs 20 Cr in Pre-Series A Round

Why It Matters

The capital infusion validates investor confidence in non‑invasive, wearable pain‑relief solutions and positions CURAPOD to capture a fast‑growing segment of the Indian health‑tech market.

Key Takeaways

• Raised Rs 20 Cr for R&D and scaling.
• Device uses FDA‑registered photobiomodulation therapy.
• Targets 30+ musculoskeletal conditions drug‑free.
• Expanding DTC sales and gym partnerships.
• Clinician‑led model drives adoption across India.

Pulse Analysis

The Indian health‑tech sector has entered a rapid expansion phase, with investors pouring capital into solutions that address chronic conditions at scale. CURAPOD’s Rs 20 crore pre‑Series A raise reflects growing confidence in wearable, drug‑free pain‑relief platforms that can be deployed outside traditional clinics. As the country grapples with a rising burden of musculoskeletal disorders—driven by an aging population and an increasingly sedentary lifestyle—digital therapeutics that combine convenience with clinical credibility are becoming essential components of the broader healthcare ecosystem. These devices also align with government initiatives promoting tele‑health and preventive care, creating a favorable regulatory environment for startups.

CURAPOD’s core technology relies on photobiomodulation, a low‑level light therapy that stimulates cellular repair without pharmaceuticals. The FDA registration of its device provides a rare stamp of safety and efficacy for an Indian‑origin wearable, helping it overcome the skepticism that often surrounds new medical gadgets. Competitors such as Theragun and Oura focus on performance tracking or muscle recovery, but few combine clinically validated light therapy with a dedicated companion app. This differentiation positions CURAPOD to capture a niche that bridges physiotherapy and consumer wellness. Clinician endorsement further accelerates adoption in physiotherapy clinics.

The fresh funding will enable CURAPOD to scale manufacturing, enhance its mobile platform, and deepen partnerships with gyms, physiotherapy centers, and sports‑medicine networks. By pursuing a direct‑to‑consumer channel alongside clinician‑led referrals, the startup can tap both retail demand and professional credibility, a hybrid model that many health‑tech firms struggle to execute. For investors, the round signals confidence that non‑invasive pain solutions can achieve profitable unit economics in emerging markets. If the company sustains product efficacy and expands distribution, it could set a benchmark for wearable therapeutics across Asia.

Healthtech startup CURAPOD raises Rs 20 Cr in pre-Series A round

By Shashank Pathak · 10 Feb 2026, 11:59 IST

Healthtech startup CURAPOD has raised Rs 20 crore (around $2.2 million) in a pre‑Series A round led by V3 Ventures, 3i Partners, and Ideaspring Capital. CURAPOD is backed by Litemed.

The fresh capital will be used to accelerate research and development, enhance its device and companion app, scale manufacturing, and expand go‑to‑market efforts. It also plans to strengthen its direct‑to‑consumer presence, expand partnerships with gyms, physiotherapy centres, and sports‑medicine networks, and improve operational efficiencies.

Founded in 2022 by Sri Velliyur and Surya Maguluri, CURAPOD develops wearable, non‑invasive pain‑management devices focused on musculoskeletal conditions. The brand’s device uses photobiomodulation therapy and is designed to address conditions such as back pain, neck pain, knee pain, joint disorders, muscle stiffness, and sports‑related injuries.

The device is FDA‑registered and supports more than 30 musculoskeletal conditions, offering a drug‑free alternative to conventional pain‑management methods. The firm follows a clinician‑led adoption model and is expanding its footprint across India.

---

Disclaimer

Bareback Media has recently raised funding from a group of investors. Some of the investors may directly or indirectly be involved in a competing business or might be associated with other companies we might write about. This shall, however, not influence our reporting or coverage in any manner whatsoever. You may find a list of our investors here.